Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
52.56 USD | +1.70% | +1.23% | -16.29% |
04-24 | Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating | MT |
04-23 | Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.29% | 11.8B | |
-3.45% | 87.17B | |
+1.97% | 40.1B | |
+56.78% | 25.12B | |
-14.82% | 15.59B | |
-8.82% | 12B | |
-41.58% | 11.8B | |
+7.49% | 8.81B | |
-10.29% | 8.24B | |
+0.95% | 7.62B |
- Stock Market
- Equities
- INCY Stock
- News Incyte Corporation
- Incyte : Says FDA Extends Supplemental New Drug Application Review Period for Ruxolitinib